Widespread awareness of the greater propensity of risperidone to elevate prolactin may lead clinicians to routinely perform tests for hyperprolactinemia (even in patients without attributable symptoms), and subsequently to disproportionately order diagnostic procedures that revealed a coincidental pituitary tumor or false positive related to other causes of pituitary hypertrophy and/or sellar masses (such as craniopharyngiomas, Rathke's cleft cyst, lymphocytic hypophysitis and pituitary enlargement or physiologic hyperplasia) [15-17]. Here, PRL is linked to primary hypophysitis.